AbbVie and Pfizer reported contrasting Q4 earnings: AbbVie grew 10% with strong sales from Skyrizi and Rinvoq, supporting a growing, well-covered dividend. Pfizer's revenue fell 1.2%, with COVID product sales dropping sharply, causing dividend coverage to fall below free cash flow, raising sustainability concerns. AbbVie’s dividend yield is lower but backed by solid cash flow, while Pfizer’s higher yield relies on borrowing, posing risk. Investors should watch AbbVie’s drug growth and Pfizer’s cost-saving efforts and non-COVID portfolio performance in 2026.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
